LA
REVB icon

Linden Advisors’s Revelation Biosciences REVB Stock Holding History

Linden Advisors’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$6.64M – 742
2021
Q3 		$6.64M Hold
3
– – 0.04% 258
2021
Q2 		$6.59M Hold
3
– – 0.03% 274
2021
Q1 		$6.58M Hold
3
– – 0.05% 249
2020
Q4 		$6.83M Buy
+3
New +$6.05M 0.05% 204

Other funds holding REVB

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
LSC
Logan Stone Capital Chicago, Illinois $473M AUM 0.79% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Linden Advisors's REVB Position: Q4 2021 in Review

Linden Advisors sold out of Revelation Biosciences (REVB) in Q4 2021, closing a stake of 3 shares — an estimated $6.64M sold.

Linden Advisors first reported a position in REVB in Q4 2020 and held it in 4 quarters. The position peaked at $6.83M in Q4 2020. 7 funds tracked by Wall St. Rank hold REVB as of Q4 2021.

  • Linden Advisors reported no remaining Revelation Biosciences position as of Q4 2021 after selling out during the quarter.
  • Linden Advisors sold 3 Revelation Biosciences shares in Q4 2021, an estimated $6.64M.
  • Linden Advisors first reported a position in Revelation Biosciences in Q4 2020 and held it in 4 quarters.
  • Linden Advisors's Revelation Biosciences position peaked at $6.83M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Revelation Biosciences as of Q4 2021.

Based on Linden Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.